Case series
Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)

https://doi.org/10.1016/j.gore.2020.100546Get rights and content
Under a Creative Commons license
open access

Highlights

  • •

    PI3K/AKT pathway alterations are frequently seen in ovarian cancer, providing rationale for targeted AKT inhibition.

  • •

    AKT inhibitor MK-2206 in platinum resistant high grade serous ovarian cancer was notable for dermatologic toxicity.

  • •

    Best response of stable disease was seen, with one patient experiencing a prolonged SD of 19 weeks.

Abstract

Platinum-resistant, recurrent, high grade epithelial ovarian carcinoma remains challenging to treat. Chemotherapy produces limited responses with modest survival benefits in the treatment of recurrent disease. In this context, targeted therapies may improve upon conventional therapies. PI3K/AKT pathway alterations are frequently found in several cancer types, including ovarian cancer, and thus AKT inhibition is a rational targeted therapy. Here we report the results of an abbreviated trial of AKT inhibitor MK-2206 in platinum resistant high grade serous ovarian, fallopian tube, and primary peritoneal cancer with PTEN loss.

Keywords

MK-2206
AKT inhibitor
PI3K/AKT pathway
PTEN
Platinum resistant ovarian cancer
Serous ovarian carcinoma

Cited by (0)

1

Present address: Knight Cancer Institute, Oregon Health and Sciences University, Portland, OR.

© 2020 The Authors. Published by Elsevier Inc.